# Feedback plc Annual Report 2023 (LON:FDBK)

- Link: https://www.directorstalkinterviews.com/feedback-plc-annual-report-2023-lonfdbk/4121142971
- Published: 2024-02-16T11:10:31+00:00
- Author: Ethan Davis

**Feedback plc** (LON:FDBK) published its Annual Report 2023 on 12 September 2023.
Dr Tom Oakley, CEO of Feedback, set out the company’s business strategy and commented
on the outlook for the year ahead:

**Business strategy **

The Company’s strategy is to pursue opportunities for cross-provider care delivery
where we expect to recognise higher contract values and operational margins, within
a less competitive environment. This will predominantly be in the Community Diagnostic
Centre (“CDC”) space in the UK, for which we estimate the total addressable market
as £96m, and remote care settings in India. The Company will, however, continue 
to target its core products at traditional NHS opportunities with individual NHS
trusts around clinical communication and replacement of legacy communication methods
such as pagers and fax machines. 

The decision-making process and associated sales cycle is currently particularly
long within the NHS, due to several factors described above and, as such, the Company
is also targeting parallel market segments for our technology that require minimal
additional product development and where there is a mirror value proposition that
we understand and can sell into, such as India. More recently this has led us to
consider applications in the UK private sector which we intend to pursue in the 
next financial year. 

To date, our commercial success has been derived from our ability to leverage and
repurpose our legacy technologies, resulting in the creation of Bleepa, CareLocker
and Bleepa Box. In addition, we opportunistically seek to license components of 
our Cadran technology to third parties, generating recurring royalty revenue from
noncore assets, as demonstrated by the licensing of Cadran to Imaging Engineering
LLC in the USA for fluoroscopy image capture. The license agreement with Image Engineering
yielded royalty revenue of £0.14m (2022: £0.14m) in the period, with a minimum ongoing
annual royalty expectation of US$70k per annum until end CY2025. 

Leveraging legacy technology and developing our existing products to maximise product
market fit and maintain our competitive advantage will remain a core strategy for
the Company and will result in continued software development spend on a measured
basis. The Company will also continue its strategy of robust regulatory certification
and IP protection alongside the programme of software production as a medical device.

**Outlook**

We are delighted with the continued progress made during the period – with the shift
from legacy products. The opportunity afforded by Bleepa and CareLocker both domestically
and overseas provides us with tremendous optimism as we focus on generating new 
contracts from our ongoing dialogues with interested parties, which we believe will
further enhance levels of recurring revenue visibility. The additional paid for 
Sussex CDC extension (announced in April) further validates our strategy and we 
remain hopeful that we will be successful in the procurement process. With CDCs 
continuing to explore avenues to reduce waiting times we believe that our performance
to date provides compelling testament to our capabilities – with early results from
our current CDC programme highlighting an approximate 69% reduction in diagnostics
wait times versus the national target. 

Furthermore, we are extremely excited by global opportunities – with inroads in 
India highlighting the scalability of our solutions. Importantly, we believe that
increased regulatory demands both in the UK and India will further underpin demand.
There is increasing focus on technologies to secure the transfer and display of 
images and videos, and we believe that the landscape is very much moving in our 
favour – with digital infrastructure and digitally enabled tools seen as key solutions
to significant administrative burdens. This is especially prevalent when considering
winter pressures and the growing requirement to reduce care backlogs – and we believe
that given our pipeline and capabilities that we will be at the forefront of change
in the coming year.

[Annual-Report-2023-Published-on-September-12-2023_FINAL-1](https://www.directorstalkinterviews.com/wp-content/uploads/2024/02/Annual-Report-2023-Published-on-September-12-2023_FINAL-1.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2024/02/Annual-Report-2023-Published-on-September-12-2023_FINAL-1.pdf)

Share on:
